Premium
Acute non‐lymphocytic leukemia (ANLL) following treatment with dacarbazine for malignant melanoma
Author(s) -
Carey Robert W.,
Kunz Victoria S.
Publication year - 1987
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830250114
Subject(s) - dacarbazine , melanoma , medicine , leukemia , oncology , aplastic anemia , cancer research , adjuvant , bone marrow
Abstract ANLL followed a brief period of aplastic anemia in a man treated intensively 4 years and 3 months previously with dacarbazine as “adjuvant” therapy for malignant melanoma. This is the first reported instance in which the latency between drug exposure and onset of leukemia strongly implicates dacarbazine as a leukemogenic agent.